FDA grants priority review to Adapt Pharma’s NDA for Narcan naloxone nasal spray

Adapt Pharma announced that the FDA has accepted its filing and granted priority review to its New Drug Application for Narcan naloxone hydrochloride nasal spray for the treatment of opioid overdose. Adapt submitted the NDA in July 2015.

Lightlake Therapeutics licensed the nasal spray to Adapt in December 2014, and the FDA granted Fast Track designation for the product in February 2015.

In July 2015, the FDA also granted priority review to Indivior’s NDA for naloxone nasal spray for the treatment of opioid overdose.

Read the Adapt Pharma press release.